Omnistat
Omnistat
Indication
Dosage & Administration
- Omnistat® capsules should not be crushed, chewed or opened.
- 0.4 mg once daily taken approximately one-half hour following the same meal each
day.
- Can be increased to 0.8 mg once daily for patients who fail to respond to the 0.4
mg dose after 2 to 4 weeks of dosing .
- If discontinued or interrupted for several days, therapy should start again with the
0.4 mg once-daily dose .
* Women & Children:
- Omnistat® capsules are not for women and children .
Like all medicines, Omnistat® can cause sides effects, although not everybody gets
them.
Common (less than 1 in 10, more than 1 in 100 (1 - 10%)):
- Dizziness, particularly when going to sit or stand up.
- Abnormal ejaculation. The latter means that semen does not leave the body via the
urethra, but instead goes into the bladder. This phenomenon is harmless.
Uncommon (More than 1 in 1000, less than 1 in 100 (0,1 - 1%)):
- Headache, palpitations (the heart beats more rapidly than normal and it is also
noticeable ), reduced blood pressure e.g. when getting up quickly from a seating or
lying position sometimes associated with dizziness; runny or blocked nose
(rhinitis), diarrhoea, feeling sick and vomiting, constipation, weakness
(asthenia), rashes, itching and hives(urticaria).
Rare(More than 1 in 10,000, less than 1 in 1000 (0,01 - 0,1%)):
- Faintness and sudden local swelling of the soft tissues of the body (e.g. the throat or
tongue) difficult breathing and /or itching and rash, often as an allergic reaction
(angioedema).
Vary rare (less than 1 in 10,000 (<0,01%)):
- Priapism (painful prolonged unwanted erection for which immediate medical
treatment is required).
- Rash, inflammation and blistering of the skin and / or mucous membrane of the lips,
eyes, mouth, nasal passages or genitals (Stevens-Johnson syndrome).
- Abnormal irregular heart rhythm (atrial fibrillation, arrhythmia, tachycardia),
difficult breathing (dyspnoea).
Overdosage:-
- Overdosage with tamsulosin hydrochloride can potentially result in severe hypotensive
effects. Gastric lavage can be applied and activated charcoal and an osmotic laxative.
Laboratory data indicate that tamsulosin is 94% to 99% protein bound; therefore dialysis
is unlikely to be of benefit.
Omnistat
- Each capsule of Omnistat® contains:
Tamsulosin hydrochloride 0,4 mg.
Indecation
- Omnistat® capsules are indicated for the treatment of the signs and symptoms of
benign prostatic hyperplasia (BPH). These signs and symptoms may include
difficulty urinating (Poor stream), dribbling, urgency and having to urinate
frequently at night as well as during the day.
- Omnistat® capsules are not indicated for the treatment of hypertension.
Dosage & Administration
- Omnistat® capsules should not be crushed, chewed or opened.
- 0.4 mg once daily taken approximately one-half hour following the same meal each
day.
- Can be increased to 0.8 mg once daily for patients who fail to respond to the 0.4
mg dose after 2 to 4 weeks of dosing .
- If discontinued or interrupted for several days, therapy should start again with the
0.4 mg once-daily dose .
* Women & Children:
- Omnistat® capsules are not for women and children .
* Orthostasis
Patients beginning treatment with Omnistat® capsules should be cautioned to avoid
situations in which injury could result should syncope occur.
* Screening for Prostate Cancer
Prostate cancer and BPH frequently coexist; therefore, patients should be screened
for the presence of prostate cancer prior to treatment with Omnistat®capsules and at
regular intervals afterwards.
* Intraoperative Floppy Iris Syndrome (IFIS)
IFIS may increase the risk of eye complications during and after the operation.
* Sulfa Allergy
In patients with sulfa allergy, allergic reaction to Omnistat®capsules has been rarely
reported. If a patient reports a serious or life-threatening sulfa allergy, caution is
warranted when administering Omnistat®capsules.
Use in Specific Populations:-
* Renal impairment
Patients with renal impairment do not require an adjustment in Omnistat® capsules
dosing. However, patients with end-stage renal disease have not been studied.
* Hepatic Impairment
Patients with moderate hepatic impairment do not require an adjustment in
Omnistat®capsules dosage. Omnistat® has not been studied in patients with severe
hepatic impairment.
* Geriatric Use
Of the total number of subjects (1783) in clinical studies of tamsulosin, 36% were 65
years of age and over. No overall differences in safety or effectiveness were observed
between these subjects and younger subjects, and the other reported clinical
experience has not identified differences in responses between the elderly and
younger patients.
